TB-500 Ac-LKKTETQ record · updated 20h ago

Healing & recoveryInflammation & immuneGrade A · human clinicalResearch use only

All 4 studies Jump to the evidence Compare

What is TB-500 Ac-LKKTETQ used for?

Thymosin Beta-4 Active Fragment | Healing Peptide

How it works: Actin-sequestering peptide; promotes cell migration & angiogenesis

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection (research use)

Development stage

where TB-500 Ac-LKKTETQ sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 11 registered trials. It describes the research record, not a recommendation.

Identity

NameTB-500 Ac-LKKTETQ

Chain length—

Molecular weight—

Formula—

Structure type—

ClassHealing

Research levelLimited Research

Discovered byCurated master list · 2026

Pharmacology

MechanismActin-sequestering peptide; promotes cell migration & angiogenesis

RouteSubcutaneous injection (research use)

Half-life—

Time to peak—

Duration—

Extraction confidence0.50

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 24, 2026. How this works →

Research stats

Total studies4

Human / animal / cellular3 / 1 / 0

Highest trial phase—

Years covered2024–2026

Latest study2d ago

Publication history

20242026

Research funding

105 NIH projects · $27.9M awarded · through FY2026

Public grants naming this compound. Funding is interest, not evidence.

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 4 Semantic Scholar UniProt

Study register

4 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
From sample to insight: Onsite training and implementing mobile environmental surveillance in sub-Saharan Africa Finding83 samples sequenced using long-read metagenomic sequencing.	Human	2026	Full text read0.70
Inherited human TFIIIA deficiency disrupts T cell development FindingNot reported in abstract.	Human	2026	Full text read0.80
A Controlled Human Malaria Infection model for relapsing <i>Plasmodium vivax</i> Finding3.6 relapse infections per person-year.	Human	2026	Full text read0.80
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. FindingNot reported in abstract.	Animal	2024	Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching TB-500 Ac-LKKTETQ will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much TB-500 Ac-LKKTETQ is discussed should be drawn from it.